September’s Women’s Health Capital Review tracks 18 funding rounds totaling US$287.8 million, highlighting where capital is flowing and what the latest deals reveal about investment in women’s health.
Wearables are collecting more data about women’s bodies than ever before. Maryann Selfe explains why the opportunity in women’s health data infrastructure lies in interpreting wearable signals, validating them clinically and turning them into better healthcare decisions.
Women’s health investing can be accessed through direct investments, specialist funds or a combination of both. Maryann Selfe examines the trade-offs across expertise, diversification, access and portfolio risk.
The women’s health investment opportunity is expanding as science and technology turn longstanding healthcare gaps into scalable markets. Maryann Selfe examines the commercial evidence and the questions investors should consider before allocating capital.
Maryann Selfe explains how family offices and institutional investors can invest in women’s health through funds, direct deals and diversified platforms.
$124 trillion is transferring to women. Women’s health receives 6% of healthcare investment. These are not two separate facts. They are one investment thesis.
For private wealth professionals and the HNW clients they advise, that thesis demands a direct answer to a direct question: is women’s health actually a good investment opportunity?
Blackstone and TPG’s acquisition of Hologic isn’t just a medtech move. It’s a cultural signal. Here’s what it reveals about the next trillion-dollar frontier in women’s health.
